Prof. Fabrizio Piazza, PhD

University of Milano-Bicocca

[Prof. Fabrizio Piazza, PhD @Prof_Piazza]

With WSO and ICAAA, we reported 5 rilevant practical areas: 1. diagnosis, testing, prediction of ICH risk; 2. antithrombotic agents and vascular interventions; 3. vascular risk factors and medications; 4. CAA treatment; 5. diagnosis and treatment of CAA-ri https://t.co/1WkznP1QQb

[Prof. Fabrizio Piazza, PhD @Prof_Piazza]

Drug-Induced Amyloid-Related Imaging Abnormalities: A Neurovascular Perspective on Risk Assessment https://t.co/gTIXXVmgIM

NEW MANUSCRIPT: through neurovascular lens, we highlighted how cerebrovascular comorbidity and CAA influences risk and severity of drug-induced ARIA.

[Prof. Fabrizio Piazza, PhD @Prof_Piazza]

Explore latest insights on ARIA and CAA in AAT, focusing on:

Antibody-driven amplification of CAA-related inflammation (CAA-ri)
The ARIA Paradox
Emerging Biomarkers reshaping the pathophysiological interpretation of ARIA
Therapeutic opportunities
Safety monitoring strategies

[iCAB International @iCABNetwork]

🚨 PIA Group Webinar Alert 🚨

𝗥𝗲𝘁𝗵𝗶𝗻𝗸𝗶𝗻𝗴 𝗔𝗥𝗜𝗔: Antibody Amplified CAA-ri?

📅 Friday, April 24, 2026
⏰ 9:00 a.m. C.T.

💡 Join our V-PIA and
don’t miss this opportunity to learn from experts and engage in cutting-edge discussion.
https://t.co/hGV3Ll0jpY

[JCM MDPI @JCM_MDPI]

#mdpijcm
#2025ReviewPaper
Clinical and #Neuroradiological_Manifestations of #Cerebra_Amyloid_Angiopathy
🎯https://t.co/AHLUTMbSGQ
✍️@MlzZedde @Prof_Piazza
@MediPharma_MDPI
#small_vessel_disease; CAA-related #inflammation

[Prof. Fabrizio Piazza, PhD @Prof_Piazza]

The VCID Clinical Trials work group of the Vascular Cognitive Disorders PIA's The Basics webinar is set for March 10.

Registration link:  https://t.co/jwei5rqRZt

Become a member of ISTAART Vascular PIA and be part of the new activities we are planning!
https://t.co/5Hst4Zx6bo

[iCAB International @iCABNetwork]

𝗜���� 𝗔𝗥𝗜𝗔 𝗮𝗻 𝗮𝗱𝘃𝗲𝗿𝘀𝗲 𝗲𝘃𝗲𝗻𝘁 𝗼𝗳 𝗔𝗔𝗧 𝗶𝗻 𝗔𝗹𝘇𝗵𝗲𝗶𝗺𝗲𝗿’𝘀 𝗱𝗶𝘀𝗲𝗮𝘀𝗲, 𝗼𝗿 𝘁𝗵𝗲 𝗶𝗮𝘁𝗿𝗼𝗴𝗲𝗻𝗶𝗰𝗮𝗹𝗹𝘆 𝗶𝗻𝗱𝘂𝗰𝗲𝗱 𝗺𝗮𝗻𝗶𝗳𝗲𝘀𝘁𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗖𝗔𝗔-𝗿𝗶?

https://t.co/NP8gM7bW7h

[Prof. Fabrizio Piazza, PhD @Prof_Piazza]

#Microbiota-gut-brain axis dysregulation in #Alzheimer’s disease and its modulation through #probiotic supplementation

Fresh new published, congrats to Moira Marizzoni and many thanks to Prof. Annamaria Cattaneo and team!

@iCABNetwork
@alzassociation

https://t.co/qo4TNP0CTq

[Prof. Fabrizio Piazza, PhD @Prof_Piazza]

#Cerebrospinal Fluid #Biomarkers Profiling in Cerebral #Amyloid Angiopathy and Relationship With Disease Phenotypes

Congrats, Mattia Losa, it has been a pleasure working with you and the whole team!

@iCABNetwork
@alzassociation
#mnesys
@unimib
https://t.co/XCVYC9ZaZa

[Prof. Fabrizio Piazza, PhD @Prof_Piazza]

#Cerebrospinal Fluid #Biomarkers Profiling in Cerebral #Amyloid Angiopathy and Relationship With Disease Phenotypes

Congrats, Mattia Losa, it has been a pleasure working with you and the whole team!

@iCABNetwork
@alzassociation
#mnesys
@unimib
https://t.co/XCVYC9ZaZa

[iCAB International @iCABNetwork]

#Donanemab receives positive opinion from the European Medicine Agency Committee for Medicinal Products for Human Use (CHMP) in early symptomatic #Alzheimers disease.

https://t.co/bzJNe1oUN8

[Prof. Fabrizio Piazza, PhD @Prof_Piazza]

Cracking the code of cerebral amyloid angiopathy in AD.

- Neuropathology of CAA and Its Comorbidity with AD (Prof. Jaunmuktane Z)

- Rethinking ARIA in Alzheimer’s Immunotherapy: Iatrogenic CAA-ri. (Prof. Piazza F)

online. Jun 13, 2025 at 4:30pm (CEST)

https://t.co/uHuAWKMhdb

[iCAB International @iCABNetwork]

#Hemostasis components in cerebral #amyloid angiopathy and #Alzheimer disease

Contribution of hemostasis components to Aβ deposition, endothelial and BBB dysfunction, vessel fragility, cerebral bleeding, and cognitive changes.
https://t.co/bsPdBxAmXD

#donanemab #lecanemab

[iCAB International @iCABNetwork]

Comment by #European #AlzheimersDisease Consortium (EADC) investigators on the negative recommendation of the CHMP on the marketing authorization of #donanemab for early Alzheimer’ s disease

https://t.co/7Z4aTsXInN

@EMA_News @alzassociation #VascularPIA @unimib

[Prof. Fabrizio Piazza, PhD @Prof_Piazza]

https://t.co/0quduZmDT3

@EliLillyItalia
@unimib
@alzassociation
@SINdem_Ass

[Prof. Fabrizio Piazza, PhD @Prof_Piazza]

Cracking the code of cerebral amyloid angiopathy in AD.

- Neuropathology of CAA and Its Comorbidity with AD (Prof. Jaunmuktane Z)

- Rethinking ARIA in Alzheimer’s Immunotherapy: Iatrogenic CAA-ri. (Prof. Piazza F)

online. Jun 13, 2025 at 4:30pm (CEST)

https://t.co/uHuAWKMhdb

[Prof. Fabrizio Piazza, PhD @Prof_Piazza]

#lecanemab
#donanemab
@eisaiusneuro
@biogen
@EliLillyItalia
@SINdem_Ass
https://t.co/lfDmKyd4CY

[Prof. Fabrizio Piazza, PhD @Prof_Piazza]

Anti-amyloid treatments, a therapeutic revolution, ready for Europe https://t.co/lfDmKyd4CY

[Prof. Fabrizio Piazza, PhD @Prof_Piazza]

Clinical and Neuroradiological Manifestations of Cerebral Amyloid Angiopathy: A Closer Look into the Natural History of a Frequent Disease https://t.co/DZIBMQ1EOj #mdpijcm

[Prof. Fabrizio Piazza, PhD @Prof_Piazza]

Traumatic Brain Injury and Chronic Traumatic Encephalopathy: Not Only Trigger for Neurodegeneration but Also for Cerebral Amyloid Angiopathy?
https://t.co/whXVjc8cvN #mdpibiomedicines

[Prof. Fabrizio Piazza, PhD @Prof_Piazza]

Positron Emission Tomography in Cerebral Amyloid Angiopathy: A Scoping Review https://t.co/G2IAPOoJ4l #mdpiapplsci via @Applsci